MORRIS PLAINS, N.J., May 18, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that final results from their Phase I/II study of veltuzumab in patients with non-Hodgkin’s lymphoma (NHL) were published online in the Journal of Clinical Oncology, entitled “Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results,” by F. Morschhauser, J.P. Leonard, L. Fayad, B. Coiffier, M. Petillon, M. Coleman, S.J. Schuster, M.J.S. Dyer, H. Horne, N. Teoh, W.A. Wegener, and D.M. Goldenberg.
